Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Expenses (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Operating Expenses data on record, last reported at $153.5 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 24.15% year-over-year to $153.5 million; the TTM value through Dec 2025 reached $543.4 million, up 28.02%, while the annual FY2025 figure was $543.4 million, 28.02% up from the prior year.
  • Operating Expenses reached $153.5 million in Q4 2025 per MIRM's latest filing, up from $130.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $153.5 million in Q4 2025 and bottomed at $45.6 million in Q1 2022.
  • Average Operating Expenses over 5 years is $83.2 million, with a median of $67.5 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 120.22% in 2021, then decreased 4.17% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $48.7 million in 2021, then rose by 27.41% to $62.1 million in 2022, then skyrocketed by 64.56% to $102.1 million in 2023, then rose by 21.05% to $123.6 million in 2024, then grew by 24.15% to $153.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $153.5 million in Q4 2025, $130.4 million in Q3 2025, and $132.8 million in Q2 2025.